FYI - For Your Innovation
Quantifying Quantum Computing And AI Drug Development | The Brainstorm EP 72
Dec 18, 2024
Brett Winton, ARK's Chief Futurist and a leading voice in technology, shares insights on the frontier of quantum computing and AI in drug development. The discussion kicks off with Google's groundbreaking quantum chip announcement, unveiling its enormous potential. They tackle the unique challenges facing quantum tech and explore the exciting collaboration between GlaxoSmithKline and Relation Therapeutics. Winton emphasizes AI's role in transforming drug trials, aiming for reduced costs and better patient outcomes, sparking a shift in the pharmaceutical landscape.
31:17
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Quantum computing's commercial viability may remain elusive for another 15 years despite Google's advancements in quantum technology.
- The partnership between GlaxoSmithKline and Relation Therapeutics illustrates AI's potential to dramatically reduce drug development costs and enhance efficiency.
Deep dives
The Current State of Quantum Computing
Google's recent announcement of their next-generation quantum chip, boasting twice the number of qubits, has stirred excitement within the tech community. Despite this advancement, the practical trajectory for quantum computing remains slow, with estimates suggesting significant commercial viability could still be 15 years away. The conversation highlights the complexity of transitioning quantum technologies from experimental setups to scalable applications, emphasizing that many companies may hype their progress to attract funding. Consequently, while quantum computing holds great promise, it continues to face substantial technical challenges that hinder rapid commercialization.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
